Attendee search 

Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse  and urinary incontinence.

Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.

The device is still at a development stage.

ID-NEST is currently developping a new, disruptive way to rebuild vascular bifurcations. Targeted indications are Aortic Arch Aneurysms and Compressed Veins. Our technology focuses on a patented way to connect 2 self-expandable stents on site, in order to restore native vessel capacities. 

endograft, stent graft, deep vein thrombosis, post-thrombotic syndrom, compressed veins, aortic arch aneurysms, self-expanding stents

Experienced and complementary team.

Scientific Committee comprises Pr Nabil Chakfé (Strasbourg), Dr Philippe Nicolini (Lyon), Pr Gerard O'Sullivan (Galway), Pr Stephen Black (London), Pr Armando Mansilha (Porto), Dr Olivier Hartung (Marseille).

Operational Team comprises:

. C. Tézenas du Montcel, CEO, MBA, 20+ years of experience at Management level in the Vascular Devices industry,

. William Wiecek, COO, 25+ years in the Medical Devices Industry. QA/RA specialist.

We're looking at a 10 millions € need, with a first slice of 2 millions € now to fund the Technological Development, followed by a 8 millions € slice to fund the clinicals

Cor-Act Advanced Technologies, developing a life supporting system, for patients dying from chronic heart failure). Cor-Act will shortly launch the first fully implantable, Cardiac Assist Device with no blood contact. Our solution is designed as a cost- effective technology to solve the growing gap between of patients waiting for a transplant / mechanical support and the actual expensive available therapies. The Cor-Act’s Cardiac Assist Device system incorporates a miniaturized implantable pump connected to silicone elements which are pressing the myocardium.

The “external fixators” (FixEx) used to date have already provided the outstanding service of stabilizing bone fractures in case of serious injuries, open bone fractures and severe joint fractures for decades. With all “external fixator” systems, four to six bone pins are screwed through the skin and into the bone. A fixation device (the actual “external fixator”) is then attached to these bone pins externally. Very often so-called “trauma fixators” are then removed after a few days or weeks once the patient’s overall condition has stabilized. The bone fracture is then definitively stabilized using a plate and screws or intramedullary nails. However, mounting the “external fixator” systems that are currently on the market is enormously time-consuming and error-prone and can only be reliably implemented by experienced orthopedic surgeons.  

The technical invention “snake FX” by the Erlangen-based startup nice!innovations GmbH has profoundly revolutionized the “external fixator” and its use in orthopedics and accident surgery. It is a conceptually completely new and an already well-developed product that enables an enormously clever, incomparably fast, incredibly simple method for stabilization of bone fractures by means of an unprecedented “snake principle”. Its “one-step rapid fixation technology” allows “snakeFX” to both fix the external fixator to the bone pins and stabilize the “FixEx” in a single step! Using traditional external fixator systems, both tasks involved time-consuming and error-prone mounting operations. Patents for “snake FX” have already been awarded for Europe, US, Brazil and Japan!

Precisely these unique selling points are leveraged when it comes to distribution: An initial estimate from Switzerland illustrates the high cost-saving potential combined with a dramatic increase in the quality of care for the patient. In Switzerland, one minute in the operating room costs 80 CHF. It takes trained orthopedic and trauma surgeons anywhere from 60 to 120 minutes for mounting and to make fine adjustments. The “snakeFX” aims to reduce this time to about 15 minutes.    

nice!innovations GmbH is currently developing the “snakeFX” into an approved product that is ready for series production. A crowd-financing campaign on www.aescuvest.de had collected more than 260,000 euros for this purpose as of February 2016 (in the form of subordinated loans). Following successful prototyping (expected in Q3/2017), snakeFX can obtain CE approval and be prepared for series production (target Q3/2018) within 9 to 12 months. The service provider for carrying out CE certification (Risk Class 1s; assessment by the “Notified Bodies” is available) has already been commissioned; a usability study with trauma surgeons, prototype-testing in a certified testing laboratory and a clinical trial are currently being conceptualized and implemented. An investor or strategic partner is being sought for the subsequent international commercialization of “snakeFX”.